Antengene (6996) Stock Overview
A clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
6996 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Antengene Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$4.38 |
| 52 Week High | HK$4.50 |
| 52 Week Low | HK$0.50 |
| Beta | 1.06 |
| 1 Month Change | 39.49% |
| 3 Month Change | 55.32% |
| 1 Year Change | 573.85% |
| 3 Year Change | -18.13% |
| 5 Year Change | n/a |
| Change since IPO | -76.04% |
Recent News & Updates
Recent updates
Revenues Tell The Story For Antengene Corporation Limited (HKG:6996)
Jan 09
The Price Is Right For Antengene Corporation Limited (HKG:6996) Even After Diving 26%
Sep 20Antengene Corporation Limited (HKG:6996) Analysts Just Slashed This Year's Estimates
Apr 03We're Not Very Worried About Antengene's (HKG:6996) Cash Burn Rate
Feb 19Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth
Nov 05We Think Antengene (HKG:6996) Can Afford To Drive Business Growth
Jun 28We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely
Mar 08We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely
Nov 18Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth
Aug 17Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth
Apr 29What Type Of Shareholders Own The Most Number of Antengene Corporation Limited (HKG:6996) Shares?
Feb 22Shareholder Returns
| 6996 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 43.6% | 12.1% | 2.1% |
| 1Y | 573.8% | 75.2% | 37.0% |
Return vs Industry: 6996 exceeded the Hong Kong Pharmaceuticals industry which returned 75.2% over the past year.
Return vs Market: 6996 exceeded the Hong Kong Market which returned 37% over the past year.
Price Volatility
| 6996 volatility | |
|---|---|
| 6996 Average Weekly Movement | 12.5% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in HK Market | 15.4% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 6996's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6996's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 169 | Jay Mei | www.antengene.com |
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company’s commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor for the treatment of cervical cancer and other advanced solid tumors.
Antengene Corporation Limited Fundamentals Summary
| 6996 fundamental statistics | |
|---|---|
| Market cap | HK$3.04b |
| Earnings (TTM) | -HK$349.08m |
| Revenue (TTM) | HK$100.54m |
Is 6996 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6996 income statement (TTM) | |
|---|---|
| Revenue | CN¥91.95m |
| Cost of Revenue | CN¥17.78m |
| Gross Profit | CN¥74.17m |
| Other Expenses | CN¥393.42m |
| Earnings | -CN¥319.25m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 80.66% |
| Net Profit Margin | -347.20% |
| Debt/Equity Ratio | 28.2% |
How did 6996 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/21 15:33 |
| End of Day Share Price | 2025/07/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Antengene Corporation Limited is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyu He | China International Capital Corporation Limited |
| Wangbin Zhou | Citigroup Inc |
| null null | CMB International Securities Limited |